Cyclo Therapeutics (CYTH)
(Delayed Data from NSDQ)
$0.77 USD
0.00 (0.52%)
Updated Oct 11, 2024 03:32 PM ET
After-Market: $0.77 0.00 (-0.52%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.77 USD
0.00 (0.52%)
Updated Oct 11, 2024 03:32 PM ET
After-Market: $0.77 0.00 (-0.52%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth F Momentum D VGM
Zacks News
Cyclo Therapeutics, Inc. (CYTH) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cyclo Therapeutics (CYTH) delivered earnings and revenue surprises of -50% and 69.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Precigen, Inc. (PGEN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and 43.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 29.79% and 361.94%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates
by Zacks Equity Research
Dare Bioscience (DARE) delivered earnings and revenue surprises of 366.67% and 96.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of -23.08% and 4.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?